Trial Profile
A retrospective study to predict the target resistance by using glasgow prognostic score as a potential marker in metastatic renal cell carcinoma patients treated with sunitinib
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 18 Aug 2015
Price :
$35
*
At a glance
- Drugs Sunitinib (Primary)
- Indications Renal cell carcinoma
- Focus Pharmacodynamics; Therapeutic Use
- 18 Aug 2015 New trial record